Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05951400
Other study ID # duphaston in ICSI for PCO
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date August 20, 2023
Est. completion date September 30, 2023

Study information

Verified date August 2023
Source Beni-Suef University
Contact Sara A Salem, MD
Phone 01272842226
Email sara_abdallah100@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the effectiveness and safety of Progesterone Primed Ovarian Stimulation protocol (PPOS) using Dydrogestrone vs GnRH Antagonist Protocol in patients with expected high ovarian response undergoing ICSI cycle


Description:

Each patient will be subjected to: Full history taking. Systematic clinical examination to assess the general condition, body mass index (BMI) and local pelvic physical findings and AFC by trans-vaginal ultrasound on D2 to 3 of menstruation. Routine labs as CBC, liver & kidney functions to exclude general disease as a contraindication for induction or pregnancy. Blood sample will be obtained for assessment of basal serum levels of FSH, LH, E2 on days 2- 3 of the cycle. PRL, AMH and TSH Ovarian Stimulation The patients will begin injections of recombinant FSH (rFSH, Gonal-F; Merck-Serono, Italy) from day 2-3 of menstruation, with daily dose of 150-300 IU adjusted according to individual conditions on the basis of the antral follicle count (AFC),hormonal profile, age, body mass index (BMI), and previous ovarian response, according to the standard operating procedures of the center. . For pituitary suppression, the patients will receive either Dydrogestrone (Duphaston 20 mg/d; Abbott Healthcare, USA) orally starting at day 2-3 or GnRH antagonist Cetrorelix (CETROTIDE 0.25Mg/d, Merck Serono, Germany) 0.25 mg/day subcutaneously from day 6 of induction until trigger day. The serum LH, estradiol levels as well as number and size of follicles will be monitored every two days, starting from stimulation day 6 until the day of hCG injection. When most of dominant follicles reach diameter of 18-22 mm, the final oocyte maturation will be induced with 0.2 mg of Triptorelin (2 amp of Decapeptyl 0.1 mg, Ferring Pharmaceuticals, the Netherlands) (agonist trigger). Then, oocyte retrieval will be performed 34-36 h later with freezing of all embryos. Frozen Embryo Transfer A maximum of 2 embryos will be transferred after endometrial preparation using Estradiol valerate(cycloprogenova 2mg tab Bayer Pharma AG, Germany) frome day 2 of cycle until endometrial thickness of 8 mm or more then adding progesterone 400 mg(Prontogest 400 IBSA pharmaceutical Italy) vaginal supp twice daily for 5 days and frozen embryo transfer will be on day 5 Transfer will be done by an expert using the same type of ET catheter under ultrasound guidance Adding progesterone 100 mg IM injection every other day if serum progesterone after 1st 4 doses of vag. Prog. is less than 9.2 ng/ml An infant born alive after 22 weeks gestation was classified as a live birth. Clinical pregnancy is defined as the presence of at least 1 gestational sac on ultrasound at 6 weeks. Ongoing pregnancy is the presence of at least 1 fetus with heart pulsation on ultrasound beyond 10 weeks. Miscarriage rate was defined as the number of miscarriages before 24 weeks divided by the number of women with clinical pregnancy. Cancellation rate is defined as the number of patients with no viable embryos to transfer divided by the number of patients that started ovarian stimulation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date September 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria: 1. undergoing trial of ICSI. 2. BMI = 30 3. AMH =3.5 4. AFC = 20 Exclusion Criteria: 1. Any known contraindications to the approved fertility drugs. 2. Severe endometriosis. 3. Uterine malformations or abnormal uterine cavity. 4. Uncontrolled endocrinopathies:DM,hyperthyroidism, hypothyroidism 5. Severe male factor 6. History of recurrent ICSI failure or recurrent miscarriage

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dydrogesterone Tablets
used for pituitary suppression in ICSI cycle
Cetrorelix
GnRH antagonist for pituitary suppression

Locations

Country Name City State
Egypt Beni-suef university Hospital Bani Suwayf Beni Suef

Sponsors (1)

Lead Sponsor Collaborator
Beni-Suef University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary oocytes retrieved Number of oocytes retrieved classified 1 month of induction for ICSI trial
Secondary Duration of stimulation days. number of days till giving trigger 1 month
Secondary chemical pregnancy rate number of pregnancy test positive 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Completed NCT04778358 - Higher Dose of Rekovelle in Oocyte Donors Phase 2
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Suspended NCT04669652 - Evaluating Piezo-ICSI. - The EPI Study. N/A
Completed NCT04524026 - RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2 Phase 2
Recruiting NCT05981898 - Opt-IVF Multi-center Trial 2 Including All Protocols N/A
Recruiting NCT05737381 - Quality of Human Embryos in IVF, Culturing in Differentiated Oxygen N/A
Recruiting NCT04447872 - The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol N/A
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Not yet recruiting NCT05932082 - The Impact of Myomectomy on IVF Outcomes N/A
Not yet recruiting NCT04283435 - Endometrial Effects of Sildenafil in Frozen-Thawed Cycles in Women With Thin Endometrium Phase 1
Recruiting NCT04654741 - The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles Phase 4
Completed NCT04099784 - Health of Frozen Transferred Versus Fresh Transferred Children
Recruiting NCT05788822 - MVA to Improve the Pregnancy Outcome in Aged Infertility Women With Assisted Reproductive Technology N/A
Completed NCT04956848 - Comparing KIDScoreā„¢ D5 and iDAScore®. The KiDA Study N/A
Not yet recruiting NCT06048666 - Platelet Rich Plasma on Ovarian Reserve Parameters and Intra Cytoplasmic Sperm Injection Outcomes in Patients With Diminished Ovarian Reserve Phase 3
Not yet recruiting NCT05954962 - Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. Phase 4
Not yet recruiting NCT02698488 - Embryo Selection by Metabolomic Profiling of Embryo Culture Medium With Mass Spectroscopy as an Adjunct to Morphology N/A
Completed NCT01385618 - Gene-polymorphisms Relating to Human Subfertility N/A